ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatitis C"

  • 2016 American Transplant Congress

    Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.

    S. Olson, A. McCann, S. Kumer, T. Schmitt, B. Floyd, R. Taylor, R. Gilroy.

    University of Kansas, Kansas City, KS.

    Background: While the primary endpoint for patients transplanted for Hepatitis C (HCV) has been established as sustained virologic response (SVR), different pathways have existed to…
  • 2016 American Transplant Congress

    Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.

    B. Amundsen,1 M. Sise,2 M. Lin,3 H. Deirawan,1 E. Heher,2 B. Kimball,1 J. Markmann,1 N. Elias.1

    1Massachusetts General Hospital, Boston, MA; 2Massachusetts General Hospital, Boston, MA; 3Brigham and Women's Hospital, Boston, MA.

    Organ shortage and expanding kidney waiting list fostered utilization of HCV positive donors' organs (HCVD+). HCVD+ kidneys have slightly worse long term outcomes compared with…
  • 2016 American Transplant Congress

    Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.

    M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.

    JHU, Baltimore.

    While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…
  • 2016 American Transplant Congress

    Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.

    N. Goyal, W. Huepfel, A. Tierney, N. Issa, J. Lake, J. Thompson, M. Hassan, H. Ibrahim, A. Kukla.

    University of Minnesota, Minneapolis.

    Background: Hepatitis C infection is associated with worse clinical outcomes in kidney transplant recipients. Direct-acting antivirals (DAAs) have been effectively used in liver transplant patients…
  • 2016 American Transplant Congress

    Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.

    S. Pol,1 A. Aghemo,2 L. Lin,3 R. Hyland,3 C. Yun,3 J. Spellman,3 M. Natha,3 D. Brainard,3 J. McHutchison,3 M. Bourlière,4 M. Peck-Radosavljevic,6 M. Michael,5 M. Colombo.2

    1Hopital Cochin, Paris, France; 2Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; 3Gilead Sciences Inc, Foster City; 4Hôpital Saint Joseph, Marseilles, France; 5Hannover Medical School, Hannover, Germany; 6Medical University of Vienna, Vienna, Austria.

    Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…
  • 2016 American Transplant Congress

    High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.

    M. Charlton,1 E. Yoshida,2 M. Bouliere,3 S. Flamm,4 A. Muir,5 M. Fried,6 N. Terrault,7 S. Arterburn,8 C. Yun,8 P. Pang,8 A. Osinusi,8 J. Spellman,8 M. Natha,8 D. Brainard,8 J. McHutchison,8 M. Manns,9 N. Afdhal.10

    1Intermountain Medical Center, Salt Lake City; 2Vancouver General Hospital, Vancouver, Canada; 3Hopital Saint Joseph, Marseilles, France; 4Northwestern University, Chicago; 5Duke University, Durham; 6University of North Carolina, Chapel Hill; 7UCSF, SF; 8Gilead Sciences Inc, Foster City; 9Hannover Medical School, Hannover, Germany; 10BIDMC, Boston.

    Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…
  • 2016 American Transplant Congress

    Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

    J. Wiegel, T. Egbuka.

    Pharmacy, Oregon Health & Science University, Portland, OR.

    Purpose: To determine if treatment of recurrent hepatitis C virus (HCV) post-liver transplant with the direct-acting antivirals (DAAs) sofosbuvir, simeprevir, and ledipasvir (in combination and/or…
  • 2016 American Transplant Congress

    Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.

    E. Verna,1 J. Levitsky,2 J. O'Leary,3 N. Bzowej,4 D. Moonka,5 R. Hyland,6 D. Brainard,6 J. McHutchison,6 N. Terrault.7

    1Columbia Univ., NY; 2Northwestern Univ., Chicago; 3Baylor Univ., Dallas; 4Ochsner Clinical Foundation, New Orleans; 5Henry Ford Hospital, Detroit; 6Gilead Sciences, Foster City; 7UCSF, San Francisco.

    Background:The optimal timing and duration of DAA therapy in HCV patients undergoing liver transplant(LT) is unknown. CRUSH-C is an open-label, Phase 2 study evaluating the…
  • 2016 American Transplant Congress

    Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.

    S. Helmke,1 J. O'Leary,2 J. Burton,1 M. Cookson,1 S. Lauriski,1 J. Trotter,2 J. McHutchison,3 G. Everson.1

    1University of Colorado, Aurora, CO; 2Baylor University Medical Center, Dallas, TX; 3Gilead Sciences, Inc., Foster City, CA.

    Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…
  • 2016 American Transplant Congress

    Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.

    A. Morales,1 M. Singla,2 H. Greenwald,1 S. Robertazzi,1 C. Rodigas,1 V. Washington,1 R. Satoskar,1 C. Smith.1

    1MedStar Transplant Institute, Georgetown University Hospital, Washington, DC; 2Gastroenterology Service, Walter Reed National Military Medical Center, Bethesda, MD.

    The purpose of this study was to assess the effect of hepatitis C virus (HCV) eradication with sofosbuvir based regimens on glycemic and lipid control…
  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences